Overview
Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after prior failed systemic therapies. It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.
Indication
适用于治疗既往两种或多种全身治疗后复发或难治性晚期肾细胞癌（RCC）的成年患者。
Associated Conditions
- Advanced Renal Cell Carcinoma
- Renal Cell Carcinoma (RCC)
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2024/10/28 | Phase 3 | Recruiting | |||
2023/11/03 | Phase 2 | Recruiting | |||
2023/11/03 | Phase 2 | Recruiting | |||
2023/09/26 | Phase 2 | Recruiting | |||
2021/08/11 | Phase 1 | Recruiting | |||
2021/08/03 | Phase 3 | Active, not recruiting | |||
2020/11/27 | Phase 1 | Recruiting | |||
2020/10/20 | Phase 1 | Terminated | |||
2019/05/31 | Phase 1 | Terminated | |||
2017/05/02 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| AVEO Pharmaceuticals, Inc. | 45629-089 | ORAL | 0.89 mg in 1 1 | 3/12/2021 | |
| AVEO Pharmaceuticals, Inc. | 45629-134 | ORAL | 1.34 mg in 1 1 | 3/12/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 8/24/2017 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.